Furthermore, the TGFB-HIGH group exhibited significantly lower estimated IC50 values to platinum-based chemotherapeutic agents in the George-SCLC cohort (p < 0.05, Supplementary Figure 2). The gene discussed is TGFB1; the disease is small cell lung carcinoma.